GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Digestive Diseases, S. Karger AG, Vol. 24, No. 1-2 ( 2006), p. 207-211
    Abstract: 〈 i 〉 Background: 〈 /i 〉 Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. Surgery has been the only effective therapy. However, many patients still eventually die of disease recurrence. Chemotherapy and radiation therapy have been of limited value. Imatinib mesylate (Glivec 〈 sup 〉 ® 〈 /sup 〉 ) is an orally administered competitive inhibitor of tyrosine kinases associated with the KIT, ABL protein, licensed for the treatment of metastatic GIST since 2002 in Germany. 〈 i 〉 Methods: 〈 /i 〉 We summarized the data of 16 patients with advanced or metastatic GIST treated with imatinib mesylate in palliative and neoadjuvant settings. 〈 i 〉 Results: 〈 /i 〉 Overall response was 81%, with no evidence of disease (NED) in 3/16 (19%), partial response (PR) in 9/16 (56%) and stable disease (SD) in 1/16 (6%), whereas 3/16 patients (19%) suffered from progressive disease (PD). Mean follow-up was 18.6 months [range: 4–30]. Mean progression-free survival (PFS) was 17.6 months [range: 0–30] , mean overall survival (OS) from initial diagnosis was 32.3 months [range: 5–122]. Most common side effects were periorbital edema and skin rash. 〈 i 〉 Conclusion: 〈 /i 〉 Imatinib mesylate is well tolerated in a dose of up to 800 mg/day and has significant activity during long- term treatment of patients with advanced or metastatic GIST.
    Type of Medium: Online Resource
    ISSN: 0257-2753 , 1421-9875
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2006
    detail.hit.zdb_id: 1482221-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Oncology, S. Karger AG, Vol. 68, No. 4-6 ( 2005), p. 326-332
    Abstract: 〈 i 〉 Background: 〈 /i 〉 Unpredictable and severe diarrhea (NCI grade ≧3) remains a life-threatening adverse event in patients treated with irinotecan (CPT-11). The aim of this study was to evaluate the efficacy and safety of orally administered budesonide for prevention of CPT-11-induced delayed diarrhea in patients with advanced colorectal cancer. 〈 i 〉 Patients and Methods: 〈 /i 〉 A total of 56 patients with advanced colorectal cancer receiving CPT-11 therapy (125 mg/m 〈 sup 〉 2 〈 /sup 〉 once weekly) were enrolled in this multicenter trial. Patients were randomly treated with 3 mg budesonide orally 3 times daily versus placebo. Detailed assessment of diarrhea by monitoring stool frequency, stool consistency and loperamide rescue medication was made by keeping a diary. 〈 i 〉 Results: 〈 /i 〉 Diarrhea, defined as number of stools 〉 4 occurring on a single day during the study period, could be prevented in 58.3% of the budesonide-treated patients compared to 38.5% of the patients under placebo. Patients in the budesonide group had less episodes (0.7 vs. 2.2 episodes) and a considerably shorter total duration of diarrhea (1.8 vs. 4.2 days) episodes than patients in the placebo group. Loperamide use was more frequent in the placebo than in the budesonide arm (55.6 vs. 41.7%). Also, exposure to rescue medication of loperamide was higher for placebo (36.2 capsules) than for budesonide (24.9 capsules). A superior prevention of diarrhea was observed for budesonide compared to placebo in the first cycle (14 vs. 10; p = 0.257), with more failures observed in the placebo group (16 vs. 10). 〈 i 〉 Conclusion: 〈 /i 〉 This double-blind randomized trial failed to show that budesonide has a significant benefit in preventing CPT-11-induced diarrhea. While a trend exists, further trials are warranted.
    Type of Medium: Online Resource
    ISSN: 0030-2414 , 1423-0232
    RVK:
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2005
    detail.hit.zdb_id: 1483096-6
    detail.hit.zdb_id: 250101-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...